Background: Several ursodeoxycholic acid (UDCA) treatment response definitions have been introduced in
Some patients complain of hair thinning, stomach upset (particularly bloating and diarrhea), and weight
First line Ursodeoxycholic acid (UDCA) treatment improves the cholestatic surrogate markers, and was recently associated with a favorable survival free of liver
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential
Abstract
Little is known about the prevalence and impact of GD on the clinical course of PBC
Eligible Objectives: Adding fibrates improves liver biochemistries in patients with primary biliary cholangitis (PBC) and suboptimal response to ursodeoxycholic acid (UDCA)
Ursodiol has been linked to rare instances of transient and mild serum aminotransferase elevations during therapy and to rare instances of jaundice and
Fibrates, which are agonists of peroxisome proliferator-activated receptors, in combination with ursodeoxycholic acid, have shown potential benefit in patients with
To date, rates of non-response to UDCA from real-world series are lacking
Objective: This study aimed to assess the prevalence of incomplete response to UDCA and determine associated patients'
Ursodiol and obeticholic acid are FDA-approved for the treatment of primary biliary cholangitis
With the development of new drugs, some patients may benefit from an earlier introduction of second-line therapies
MM First-line treatment of patients with primary biliary cholangitis (PBC) currently consists of ursodeoxycholic acid (UDCA) at 13 to 15 mg/kg per day, usually divided in twice-daily doses
Discussion In cholestasis, the primary mode of action of UDCA [ 9 ], an epimer of chenodeoxycholic acid (CDCA) but no FXR agonist properties, is thought to be choleretic by facilitating bile flow rather than Background: Many patients with primary biliary cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid
Ursodeoxycholic acid seemed to have a beneficial effect on liver biochemistry measures and on Primary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis
Primary biliary cholangitis (PBC) is a chronic and usually slowly progressive liver disease with autoimmune features
We performed a systematic review and meta-analysis to assess the efficacy and harms of BZF monotherapy or combination therapy